Laura Panjwani

Articles

Stopping TKIs Proven Safe in Chronic Phase CML

June 11th 2016

Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.

Expert Addresses Sequencing and Resistance With Immunotherapy in Melanoma

June 10th 2016

Keith T. Flaherty, MD, discusses choosing between immunotherapy and targeted therapy in the frontline setting for patients with BRAF-mutated melanoma.

Despite Recommendations, Aggressive Cancer Treatment Still Common at End of Life

June 6th 2016

An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.

Daratumumab Combo Shows Unprecedented PFS Benefit in Multiple Myeloma

June 5th 2016

Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%, and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.

Molecular Targeting Yields Responses in 12 Cancers in Off-Label Indications

June 5th 2016

Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.

Polyp Mutations May Hold Key to CRC Prevention

May 31st 2016

Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.

Novel Treatments, Effective Combinations Still Needed in Thyroid Cancer

May 26th 2016

Keith C. Bible, MD, PhD, discusses novel treatments he is excited about, the role of lenvatinib, and what the future may hold for thyroid cancer treatment.

Role of Cetuximab Expands in Head and Neck Cancer

May 25th 2016

James Melotek, MD, discusses two clinical trials looking at the impact of cetuximab in patients with squamous cell carcinoma of the head and neck.

Expert Explains Role for Newly Approved TKI/mTOR Combo in RCC

May 25th 2016

Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Expert Discusses Promise of Nivolumab in Head and Neck Cancer

May 24th 2016

Robert Ferris, MD, PhD, explains the potential of nivolumab, its future, and its limitations in the treatment of patients with head and neck cancer.

Retreatment With Radium-223 Found Safe in mCRPC

May 21st 2016

Luke Nordquist, MD, discusses a study investigating a higher dose of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and the ongoing potential of the agent in treating the disease.

Stem Cell Transplant Continues to Show Benefit in 'Novel-Agent Era' of Multiple Myeloma

May 19th 2016

Early findings from a phase III clinical trial suggest that patients with multiple myeloma who receive upfront autologous stem cell transplant survive longer without disease progression than those who receive chemotherapy alone.

Expert Discusses Promise of CRS-207 Vaccine in Mesothelioma

May 16th 2016

Thierry M. Jahan, MD, discusses a study looking at the investigational cancer vaccine CRS-207 and its potential in mesothelioma.

Further Steps Needed to Unleash Full Potential of Immunotherapy in Lung Cancer

May 13th 2016

John Haanen, MD, PhD, discusses why the best combination regimens and the ideal patient population for immunotherapy treatments in lung cancer are still largely unknown.

Hedgehog Inhibitors Transform Treatment of Advanced Basal Cell Carcinoma

May 9th 2016

Desiree Ratner, MD, discusses what oncologists should know about hedgehog inhibitors in advanced basal cell carcinoma and what the future holds for these agents.

APRIL/BCMA Targeted Agent May Block Tumor Growth, Drug Resistance in Myeloma

May 5th 2016

Kenneth Anderson, MD, PhD, discusses the role of APRIL/BCMA and what potential the targeted agent BION-1301 may have in blocking multiple myeloma cell proliferation, as well as reducing drug resistance and immunosuppression in the tumor microenvironment.

Combining Vismodegib With Radiation May Benefit Patients With Basal Cell Carcinoma

May 2nd 2016

Chris Barker, MD, discusses a study investigating radiation therapy plus the hedgehog pathway inhibitor vismodegib (Erivedge) in patients with locally advanced basal cell carcinoma of the head and neck.

Early Intervention With Lenalidomide Examined in Smoldering Myeloma

May 2nd 2016

In an ongoing randomized phase III trial, researchers are looking at lenalidomide (Revlimid) compared with observation in patients with asymptomatic high-risk smoldering multiple myeloma.

Expert Discusses Latest Findings With Nivolumab/Ipilimumab Combo in Melanoma

April 29th 2016

Patrick Ott, MD, PhD, discusses toxicity management and patient selection considerations required with the combination of nivolumab (Opdivo)/ipilimumab (Yervoy), and its role in BRAF-mutant melanoma.

Melanoma Combinations: Going Beyond Ipilimumab/Nivolumab

April 27th 2016

Omid Hamid, MD, outlines a selection of combinations that are on the horizon in advanced melanoma.